Maternal iron deficiency at term or near term (as defined by authors of the trials, based on any indicator of iron status at 34 weeks' gestation or more) · women during pregnancy

1 finding from 1 review

Multiple micronutrient powders for home (point‐of‐use) fortification of foods in pregnant women 2015 · Cochrane Headline outcomes only
no estimate extracted
0 participants
GRADE not reported

Home (point‐of‐use) fortification of foods with multiple micronutrient powders vs iron folic acid (IFA)

Maternal death · women during pregnancy

1 finding from 1 review

Multiple micronutrient powders for home (point‐of‐use) fortification of foods in pregnant women 2015 · Cochrane Headline outcomes only
no estimate extracted
0 participants
GRADE not reported

Home (point‐of‐use) fortification of foods with multiple micronutrient powders vs iron folic acid (IFA)

Adverse effects (any)* · women during pregnancy

1 finding from 1 review

Multiple micronutrient powders for home (point‐of‐use) fortification of foods in pregnant women 2015 · Cochrane Headline outcomes only
no estimate extracted
0 participants
GRADE not reported

Home (point‐of‐use) fortification of foods with multiple micronutrient powders vs iron folic acid (IFA)

Low birthweight · women during pregnancy

1 finding from 1 review

Multiple micronutrient powders for home (point‐of‐use) fortification of foods in pregnant women 2015 · Cochrane Headline outcomes only
no estimate extracted
0 participants
GRADE not reported

Home (point‐of‐use) fortification of foods with multiple micronutrient powders vs iron folic acid (IFA)

Preterm birth · women during pregnancy

1 finding from 1 review

Multiple micronutrient powders for home (point‐of‐use) fortification of foods in pregnant women 2015 · Cochrane Headline outcomes only
no estimate extracted
0 participants
GRADE not reported

Intervention not reported

Cardiovascular event · people with primary prevention of cardiovascular disease in

The intervention showed no clear difference in cardiovascular event (low certainty).

1 finding from 1 review

Multiple risk factor interventions for primary prevention of cardiovascular disease in low‐ and middle‐income countries 2015 · Cochrane Headline outcomes only
RR 0.57 [0.11, 3.07]
1 study · 232 participants
Low

Intervention not reported

Systolic blood pressure, change from baseline (mmHg) · people with primary prevention of cardiovascular disease in

1 finding from 1 review

Multiple risk factor interventions for primary prevention of cardiovascular disease in low‐ and middle‐income countries 2015 · Cochrane Headline outcomes only
no estimate extracted
11 studies · 4868 participants
Low

Intervention not reported

Diastolic blood pressure, change from baseline (mmHg) · people with primary prevention of cardiovascular disease in

1 finding from 1 review

Multiple risk factor interventions for primary prevention of cardiovascular disease in low‐ and middle‐income countries 2015 · Cochrane Headline outcomes only
no estimate extracted
11 studies · 4701 participants
Low

Intervention not reported

Body mass index, change from baseline (kg/m2) · people with primary prevention of cardiovascular disease in

1 finding from 1 review

Multiple risk factor interventions for primary prevention of cardiovascular disease in low‐ and middle‐income countries 2015 · Cochrane Headline outcomes only
no estimate extracted
7 studies · 2984 participants
Low

Intervention not reported

Waist circumference, change from baseline (cm) · people with primary prevention of cardiovascular disease in

1 finding from 1 review

Multiple risk factor interventions for primary prevention of cardiovascular disease in low‐ and middle‐income countries 2015 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 393 participants
Moderate

Intervention not reported

Comparison intervention

The review found no eligible studies for this question.

1 finding from 1 review

Immunomodulators and immunosuppressants for multiple sclerosis: a network meta‐analysis 2013 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

placebo

The review found no eligible studies for this question.

1 finding from 1 review

Immunomodulators and immunosuppressants for multiple sclerosis: a network meta‐analysis 2013 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

IFNß‐1a (Avonex)

The review found no eligible studies for this question.

1 finding from 1 review

Immunomodulators and immunosuppressants for multiple sclerosis: a network meta‐analysis 2013 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

IFNß‐1a (Rebif)

The review found no eligible studies for this question.

1 finding from 1 review

Immunomodulators and immunosuppressants for multiple sclerosis: a network meta‐analysis 2013 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

IFNß‐1b (Betaseron)

The review found no eligible studies for this question.

1 finding from 1 review

Immunomodulators and immunosuppressants for multiple sclerosis: a network meta‐analysis 2013 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found